Today, the President & CEO of TRACON Pharmaceuticals, Inc. (TCON), Charles Theuer, bought shares of TCON for $22.5K.
This recent transaction increases Charles Theuer’s holding in the company by 40.46% to a total of $78.1K.
See today’s analyst top recommended stocks >>
Currently, TRACON Pharmaceuticals, Inc. has an average volume of 83.11K.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, ophthalmic, and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types; TRC205 created for the treatment of fibrotic diseases; and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.
